Company intelligence / Profile preview

Shuimu BioSciences

Ownership: Private
Employees: ~51
Development stage: Preclinical

Overview

Shuimu BioSciences operates the world’s largest commercial cryo-electron microscopy facility in Asia-Pacific and provides high-throughput cryoEM and AI-driven structure determination services for drug discovery. Their technology enables rapid atomic-level modeling of biomolecules—proteins, antibodies, nucleic acids—accelerating rational drug design for pharmaceutical and biotech partners globally. They have supported over 100 pharma/biotech companies and academic institutions since founding in 2017.

Modalities: ProteinAntibodyNucleic acidSmall moleculeNanobody therapy
Industry: Drug Discovery Services

Partnerships

Thermo Fisher Scientific (built first commercial cryoEM facility in Asia-Pacific together)

Beyond the preview

Go deeper on Shuimu BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shuimu BioSciences.

Explore the full profile